Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.

Barroso-Sousa R, Tarantino P, Tayob N, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Hu J, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Briccetti F, Schneider B, Garrett AM, Marcom K, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu M, Ruddy KJ, Zheng Y, Rosenberg SM, Gelber RD, Trippa L, Barry W, DeMeo M, Burstein H, Partridge A, Winer EP, Krop I, Tolaney SM

Open source

DOI: 10.1038/s41523-022-00385-2
Published: 2022 Feb 16
Container: NPJ breast cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41523-022-00385-2,
  title = {Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.},
  author = {Barroso-Sousa R and Tarantino P and Tayob N and Dang C and Yardley DA and Isakoff SJ and Valero V and Faggen M and Mulvey T and Bose R and Hu J and Weckstein D and Wolff AC and Reeder-Hayes K and Rugo HS and Ramaswamy B and Zuckerman D and Hart L and Gadi VK and Constantine M and Cheng K and Briccetti F and Schneider B and Garrett AM and Marcom K and Albain K and DeFusco P and Tung N and Ardman B and Nanda R and Jankowitz RC and Rimawi M and Abramson V and Pohlmann PR and Van Poznak C and Forero-Torres A and Liu M and Ruddy KJ and Zheng Y and Rosenberg SM and Gelber RD and Trippa L and Barry W and DeMeo M and Burstein H and Partridge A and Winer EP and Krop I and Tolaney SM},
  year = {2022},
  journal = {NPJ breast cancer},
  doi = {10.1038/s41523-022-00385-2},
  url = {https://doi.org/10.1038/s41523-022-00385-2}
}

RIS

TY  - JOUR
TI  - Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.
AU  - Barroso-Sousa R
AU  - Tarantino P
AU  - Tayob N
AU  - Dang C
AU  - Yardley DA
AU  - Isakoff SJ
AU  - Valero V
AU  - Faggen M
AU  - Mulvey T
AU  - Bose R
AU  - Hu J
AU  - Weckstein D
AU  - Wolff AC
AU  - Reeder-Hayes K
AU  - Rugo HS
AU  - Ramaswamy B
AU  - Zuckerman D
AU  - Hart L
AU  - Gadi VK
AU  - Constantine M
AU  - Cheng K
AU  - Briccetti F
AU  - Schneider B
AU  - Garrett AM
AU  - Marcom K
AU  - Albain K
AU  - DeFusco P
AU  - Tung N
AU  - Ardman B
AU  - Nanda R
AU  - Jankowitz RC
AU  - Rimawi M
AU  - Abramson V
AU  - Pohlmann PR
AU  - Van Poznak C
AU  - Forero-Torres A
AU  - Liu M
AU  - Ruddy KJ
AU  - Zheng Y
AU  - Rosenberg SM
AU  - Gelber RD
AU  - Trippa L
AU  - Barry W
AU  - DeMeo M
AU  - Burstein H
AU  - Partridge A
AU  - Winer EP
AU  - Krop I
AU  - Tolaney SM
PY  - 2022
JO  - NPJ breast cancer
DO  - 10.1038/s41523-022-00385-2
UR  - https://doi.org/10.1038/s41523-022-00385-2
ER  -

APA

R, B., P, T., N, T., C, D., DA, Y., SJ, I., V, V., M, F., T, M., R, B., J, H., D, W., AC, W., K, R., HS, R., B, R., D, Z., L, H., VK, G., M, C., K, C., F, B., B, S., AM, G., K, M., K, A., P, D., N, T., B, A., R, N., RC, J., M, R., V, A., PR, P., C, V. P., A, F., M, L., KJ, R., Y, Z., SM, R., RD, G., L, T., W, B., M, D., H, B., A, P., EP, W., I, K., & SM, T. (2022). Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.. NPJ breast cancer. https://doi.org/10.1038/s41523-022-00385-2

Source records

pubmed · retrieved 2026-09-27T15:10:30.570Z